Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | COMT | P21964 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924070 | 0.80 | HTR6 (0.59) | KMT2AALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL8865655 | 0.79 | TSHR (0.60) | KMT2AALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL7266282 | 0.79 | LMNA (0.46) | GAAKMT2ACOMTKDM4ELMNA | |
| SCHEMBL11032457 | 0.79 | GAA (0.54) | GAAKMT2APAX8COMTALDH1A1 | |
| SCHEMBL7266007 | 0.79 | PKM (0.64) | GAAKMT2AHTTSMN1; SMN2KDM4E | |
| SCHEMBL10973535 | 0.79 | GAA (0.54) | GAAKMT2APAX8ALDH1A1HTT | |
| SCHEMBL7459868 | 0.79 | KDM4E (0.69) | GAAKMT2APAX8COMTALDH1A1 | |
| SCHEMBL13694354 | 0.77 | KMT2A (0.71) | GAAKMT2APAX8COMTALDH1A1 | |
| SCHEMBL4400955 | 0.77 | GAA (1.00) | GAAKMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL170033 | 0.77 | GAA (1.00) | GAAKMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (GB) | 2006-03-23 | — | — | US | claimed |
| EP-1531821-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNYL MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004006927-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| EP-1934238-B1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1056771-B1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-11-30 | — | — | EP | disclosed |
| EP-1531821-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNYL MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006927-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| EP-1056771-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043699-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | MMP9, MMP2, TIMP3 | GAA 174/4885KMT2A 1763/4885PAX8 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.